



ViroPharma Incorporated
Investor Relations Department
730 Stockton Drive
Exton, PA 19341
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: VPHM¹

Last Trade:	24.36
Trade Time:	10:16 AM ET Dec 12, 2012
Change:	0.01 (0.057%)
Day Range	24.35 - 24.50
52-Week Range	19.02 - 33.17
Volume	30,000
Market Cap. (\$M)	1,605.783
Shares Out (M)	65.908

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Thank you for exploring the ViroPharma story. One of our primary priorities is to communicate effectively with you, our current and potential shareholders. You have many options to consider for your investment dollars, so we appreciate your time and attention.

ViroPharma is rare among biotechnology companies. We are in the enviable position of having a strong and growing balance sheet; a promising pipeline with novel drugs targeting great unmet medical needs and serious diseases; two FDA approved products that are today saving and improving lives: Vancocin® which treats two significant bacterial infections of the lower gastrointestinal tract; and Cinryze™ (C1 Esterase Inhibitor [Human]) which is indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE); and an excellent and experienced team throughout our global organization.

We will continue to leverage our clinical and business development expertise and our balance sheet to expeditiously develop our current pipeline, maximize the opportunities for success of our marketed products, and bring new product opportunities into the company. Through our efforts, we believe that we will be successful in providing great value to our shareholders, our employees, the patients we seek to treat, and the physicians who treat them. At ViroPharma, we believe that the work we are doing today throughout our organization will enable us to reach our goals.

Be well –

Stock Performance



Press Releases [\[View all \]](#)

Dec 12, 2012
[ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema](#)

Nov 29, 2012
[ViroPharma To Participate In Two December Healthcare Investor Conferences](#)

Nov 13, 2012
[ViroPharma's Cinryze® \(C1 Esterase Inhibitor \[Human\]\) Prophylaxis Study Showed Safety Data of Escalating Doses in Patients With Hereditary Angioedema](#)

Nov 8, 2012
[ViroPharma To Participate In Two November Healthcare Investor Conferences](#)

Oct 25, 2012
[ViroPharma Incorporated Reports Third Quarter 2012 Financial Results](#)

Events [\[View all \]](#)

Dec 13, 2012 1:35 PM ET
[Oppenheimer 23rd Annual Healthcare Conference](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Feb 28, 2012
[Annual Report \(10-K\)](#)

Apr 13, 2012
[Definitive Proxy Statement](#)

Oct 25, 2012
[Quarterly Report \(10-Q\)](#)

Aug 9, 2012
[Quarterly Report \(10-Q\)](#)

May 1, 2012
[Quarterly Report \(10-Q\)](#)



**Vincent
Milano,**
President
and Chief
Executive
Officer

... [\(more\)](#)

NASDAQ OMX